Ask AI
ProCE Banner Activity

Rethinking AML Therapy: Menin Inhibitors as a New Paradigm in Precision Hematology

Clinical Thought

In this expert commentary, the scientific rationale for menin inhibitors in AML, particularly KMT2A-rearranged and mutant NPM1 AML subtypes, as well as key data from clinical trials, emerging combination strategies, toxicity management, and the future potential of these agents in frontline AML therapy are discussed.

Released: October 08, 2025

Share

Provided by

Provided by Clinical Care Options, LLC

ProCE Banner

Supporters

Supported by educational grants from Johnson & Johnson, Kura Oncology, Inc. and Syndax Pharmaceuticals, Inc. 

Johnson & Johnson

Kura Oncology, Inc.

Syndax Pharmaceuticals, Inc.

Disclosure

Primary Author

Eytan M. Stein, MD: consultant/advisor/speaker: Syndax.

Eunice S. Wang, MD: consultant/advisor/speaker: AbbVie, Astellas, Blueprint, Daiichi Sankyo, Dark Blue, Dava Oncology, GSK, Kite, Kura, Novartis, Qiagen, Rigel, Ryvu, Schrödinger , Servier, Stemline, Syndax, Pfizer, Takeda; data and safety monitoring committee: AbbVie.